EUVIMEDEUVIMED entdecken
Open Access

Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans

Versicherungsschutz und Nutzungssteuerung für Medikamente bei Alkoholgebrauchsstörung in Medicaid Managed Care Plans

Maureen T Stewart, Sage R Feltus, Christina M Andrews, Andrea Acevedo, Cindy Parks Thomas, Jeffrey Bratberg, Constance M Horgan, Dominic Hodgkin, Rachel Sayko Adams

JAMA Network Open · 13.03.2025 · 8 (3) · e250695

DOI: 10.1001/jamanetworkopen.2025.0695 ↗

Auf einen Blick

In 241 Medicaid Managed Care Plans wurde häufig mindestens ein Medikament gegen Alkoholgebrauchsstörung abgedeckt. Vor allem injizierbares Naltrexon unterlag jedoch häufiger Nutzungssteuerung.

Fragestellung

Wie ist die Abdeckung und Nutzungssteuerung von Acamprosat, Naltrexon und Disulfiram in Medicaid Managed Care Plans, und womit sind Unterschiede assoziiert?

Methode

Querschnittliche Inhaltsanalyse von Versicherungsdaten aus 2021 zu 241 umfassenden Medicaid MCPs; Auswertung mit Regressionsanalysen.

Ergebnisse

217/241 Pläne (90,0 %) deckten mindestens 1 Medikament ab. Abdeckung: Acamprosat 132 (54,7 %), orales Naltrexon 203 (84,2 %), injizierbares Naltrexon 175 (72,6 %), Disulfiram 152 (63,0 %), alle 4 Medikamente 103 (42,7 %).

Schlussfolgerung der Autor:innen

Die Autor:innen schließen, dass Bemühungen zur Ausweitung der Verordnung von AUD-Medikamenten durch Lücken im Versicherungsschutz begrenzt sein können. MCPs und Bundesstaaten können die Nutzung durch Abdeckung ohne Nutzungssteuerung unterstützen.

Kernaussagen

  • 90,0 % der Pläne deckten mindestens 1 AUD-Medikament ab
  • Injizierbares Naltrexon hatte am häufigsten Prior Authorization oder Mengenlimits
  • Nur 42,7 % deckten alle 4 Medikamente ab

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 13.03.2025. Verfasst von Maureen T Stewart und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts. Hauptthemen laut MEDLINE: Medicaid, Managed Care Programs, Alcoholism, Alcohol Deterrents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIAAA NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Evidence-based, patient-centered treatment for alcohol use disorder (AUD) can include pharmacotherapy with naltrexone, acamprosate, or disulfiram; however, these medications are rarely used. Medicaid managed care plans (MCPs) manage health services for nearly 80% of Medicaid enrollees and are the largest payer for addiction treatment services. Little is known about Medicaid MCP policies for AUD medications.

Objectives

To describe Medicaid MCPs’ coverage and management of acamprosate, naltrexone, and disulfiram for AUD and examine associations of plan characteristics and state policies with medication coverage. Design, Setting, and Participants In this cross-sectional study, a content analysis was performed of 2021 insurance benefit data for 241 comprehensive Medicaid MCPs in states using Medicaid managed care, as well as secondary sources. Data were analyzed from May to August 2024. Main Outcomes and Measures Medicaid MCP-reported medication coverage and utilization management requirements (eg, prior authorization, quantity limit requirements) for acamprosate, disulfiram, and oral and injectable naltrexone together and for each medication separately. Independent variables included plan characteristics (profit status, market share) and the state policy environment in which plans are embedded (Section 1115 substance use disorder waiver, state-defined preferred drug list). Regressions examined associations of plan characteristics and state policies with medication coverage.

Results

In this cross-sectional content analysis of 241 comprehensive Medicaid MCPs in 2021, 217 (90.0%) covered at least 1 medication for AUD: 132 (54.7%) covered acamprosate, 203 (84.2%) covered oral naltrexone, 175 (72.6%) covered injectable naltrexone, 152 (63.0%) covered disulfiram, and 103 (42.7%) covered all 4 medications. Prior authorization and quantity limits were rarely applied, except for injectable naltrexone, for which 75 plans (42.8%) imposed at least 1 of these utilization management requirements. Conclusions and Relevance This study suggests that efforts to expand AUD medication prescribing may be limited by gaps in health insurance coverage. Medicaid MCPs and states can support AUD medication utilization by covering these medications without applying utilization management strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedicaidManaged Care ProgramsAlcoholismAlcohol DeterrentsInsurance CoverageHumansUnited StatesCross-Sectional StudiesNaltrexoneDisulfiramAcamprosateMale

Substanzen

NaltrexoneDisulfiramAcamprosateAlcohol Deterrents

Autor:innen und Institutionen

  • Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts.
  • Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts.
  • Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia.
  • Booz Allen Hamilton Inc, McLean, Virginia.
  • Department of Pharmacy Practice and Clinical Research, University of Rhode Island College of Pharmacy, Kingston.

Förderung

  • NIDA NIH HHS
  • NIAAA NIH HHS

Zitieren

APA

Stewart, M. T., Feltus, S. R., Andrews, C. M., Acevedo, A., Thomas, C. P., Bratberg, J., Horgan, C. M., Hodgkin, D., & Adams, R. S. (2025). Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans. JAMA Network Open, 8(3), e250695. https://doi.org/10.1001/jamanetworkopen.2025.0695

Vancouver

Stewart MT, Feltus SR, Andrews CM, Acevedo A, Thomas CP, Bratberg J, et al. Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans. JAMA Network Open. 2025;8(3):e250695. doi:10.1001/jamanetworkopen.2025.0695

BibTeX
@article{Stewart2025,
  author = {Stewart, Maureen T and Feltus, Sage R and Andrews, Christina M and Acevedo, Andrea and Thomas, Cindy Parks and Bratberg, Jeffrey and Horgan, Constance M and Hodgkin, Dominic and Adams, Rachel Sayko},
  title = {Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {3},
  pages = {e250695},
  doi = {10.1001/jamanetworkopen.2025.0695}
}
Kostenlos starten →